Evotec SE (EVT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evotec SE (EVT) has a cash flow conversion efficiency ratio of -0.162x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-107.83 Million ≈ $-126.06 Million USD) by net assets (€665.58 Million ≈ $778.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EVT market cap for the company's overall valuation and market capitalisation.
Evotec SE - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Evotec SE's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Evotec SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evotec SE ranked by their cash flow conversion efficiency. Explore how high is Evotec SE's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hebei Jianxin Chemical Co Ltd
SHE:300107
|
0.002x |
|
Fujian Minfa Aluminium Co Ltd
SHE:002578
|
-0.035x |
|
Log-In Logística Intermodal S.A
SA:LOGN3
|
0.056x |
|
Voyager Acquisition Corp
NASDAQ:VACH
|
0.010x |
|
PIERER Mobility AG
VI:PKTM
|
0.049x |
|
Asia Aviation Public Company Limited
BK:AAV-R
|
0.164x |
|
Brightspire Capital Inc
NYSE:BRSP
|
0.012x |
|
China Oil HBP Science & Technology Co Ltd
SHE:002554
|
-0.120x |
Annual Cash Flow Conversion Efficiency for Evotec SE (2003–2025)
The table below shows the annual cash flow conversion efficiency of Evotec SE from 2003 to 2025. View Evotec SE share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €813.70 Million ≈ $951.31 Million |
€-9.44 Million ≈ $-11.03 Million |
-0.012x | -160.63% |
| 2024-12-31 | €952.52 Million ≈ $1.11 Billion |
€18.22 Million ≈ $21.30 Million |
0.019x | -41.21% |
| 2023-12-31 | €1.12 Billion ≈ $1.31 Billion |
€36.44 Million ≈ $42.60 Million |
0.033x | -80.98% |
| 2022-12-31 | €1.19 Billion ≈ $1.39 Billion |
€203.11 Million ≈ $237.45 Million |
0.171x | +92.82% |
| 2021-12-31 | €1.38 Billion ≈ $1.61 Billion |
€122.24 Million ≈ $142.91 Million |
0.089x | +43.84% |
| 2020-12-31 | €725.01 Million ≈ $847.62 Million |
€44.72 Million ≈ $52.28 Million |
0.062x | -30.30% |
| 2019-12-31 | €477.03 Million ≈ $557.70 Million |
€42.22 Million ≈ $49.35 Million |
0.088x | -75.93% |
| 2018-12-31 | €424.88 Million ≈ $496.73 Million |
€156.24 Million ≈ $182.66 Million |
0.368x | +1026.64% |
| 2017-12-31 | €331.75 Million ≈ $387.85 Million |
€10.83 Million ≈ $12.66 Million |
0.033x | -89.63% |
| 2016-12-31 | €213.94 Million ≈ $250.11 Million |
€67.36 Million ≈ $78.75 Million |
0.315x | +276.39% |
| 2015-12-31 | €187.09 Million ≈ $218.73 Million |
€15.65 Million ≈ $18.30 Million |
0.084x | +448.94% |
| 2014-12-31 | €158.38 Million ≈ $185.17 Million |
€-3.80 Million ≈ $-4.44 Million |
-0.024x | -157.25% |
| 2013-12-31 | €158.97 Million ≈ $185.85 Million |
€6.66 Million ≈ $7.78 Million |
0.042x | -46.57% |
| 2012-12-31 | €152.55 Million ≈ $178.34 Million |
€11.96 Million ≈ $13.98 Million |
0.078x | +13.75% |
| 2011-12-31 | €147.25 Million ≈ $172.14 Million |
€10.15 Million ≈ $11.86 Million |
0.069x | +916.62% |
| 2010-12-31 | €132.64 Million ≈ $155.07 Million |
€899.00K ≈ $1.05 Million |
0.007x | +103.46% |
| 2009-12-31 | €111.49 Million ≈ $130.34 Million |
€-21.85 Million ≈ $-25.55 Million |
-0.196x | +28.84% |
| 2008-12-31 | €149.86 Million ≈ $175.20 Million |
€-41.28 Million ≈ $-48.26 Million |
-0.275x | -48.33% |
| 2007-12-31 | €170.55 Million ≈ $199.39 Million |
€-31.67 Million ≈ $-37.03 Million |
-0.186x | -176.14% |
| 2006-12-31 | €137.18 Million ≈ $160.37 Million |
€-9.22 Million ≈ $-10.78 Million |
-0.067x | -367.85% |
| 2005-12-31 | €148.67 Million ≈ $173.81 Million |
€-2.14 Million ≈ $-2.50 Million |
-0.014x | +95.23% |
| 2004-12-31 | €61.73 Million ≈ $72.17 Million |
€-18.60 Million ≈ $-21.74 Million |
-0.301x | +22.58% |
| 2003-12-31 | €36.03 Million ≈ $42.12 Million |
€-14.02 Million ≈ $-16.39 Million |
-0.389x | -- |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more